An interventional study of Nanotite dental implant and Osseotite dental implant in Tooth Disease and Partial Edentulism, sponsored by ZimVie. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by ZimVie · Not applicable, Interventional, and Treatment
This study will evaluate the contributions of the Nanotite implant design when used by graduate students in their first year of placing implants.
This multicenter, prospective, randomized-controlled study will compare the performance of the Nanotite vs. the standard Ossotite implants when placed by graduate students with little or no prior experience. Enrolled patients will have the study site(s) randomized to either a Nanotite (test) or an Osseotite (control) implant. The manner of treatment observed at the participating center will be followed for this study.
Study Hypothesis: The performance of the Nanotite implant in this study will be no different than or superior to that of the Osseotite implant placed during the early period of graduate student training.
79 studies on the registry are indexed under Tooth Diseases; 11 are open to participants now.
This study's enrollment of 241 is above the median of 49 across 63 interventional studies indexed under Tooth Diseases.
Browse Tooth Diseases studies →ZimVie is the lead sponsor of 24 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Nanotite dental implant
Device: Nanotite dental implant
Osseotite dental implant
Device: Osseotite dental implant
Nanotite root form titanium dental implant
Also known as: Nanotite endosseous dental implant
Osseotite Root form titanium dental implant
Also known as: Osseotite endosseous dental implant
Integration Success of the Implant
Time frame: 1 year
Up to 165 patients are expected to be enrolled across all centers, with enrollment efforts beginning in August 2008. Enrollment period remained opent until December 2010.
| Milestone | Nanotite Implant | Osseotite Implant |
|---|---|---|
| Started | 122 | 119 |
| Completed | 113 | 112 |
| Not completed | 9 | 7 |
| Withdrew: Adverse event | 9 | 7 |
| implants | Nanotite Implant | Osseotite Implant |
|---|---|---|
| Integration Success of the Implant | 230 | 239 |
Collected over Adverse events are collected and reported throughout the duration of the study, an average of 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nanotite Implant | — | 0/122 (0%) | 9/122 (7.4%) |
| Osseotite Implant | — | 0/119 (0%) | 7/119 (5.9%) |
| Event | Nanotite Implant | Osseotite Implant |
|---|---|---|
| Loss of integration of implantSurgical and medical procedures | 9/122 | 7/119 |
Nanotite implants = 239 Osseotite implants = 246
| Age, Categorical(Participants) | Nanotite Implant | Osseotite Implant | Total |
|---|---|---|---|
| <=18 years | 1 | 0 | 1 |
| Between 18 and 65 years | 61 | 63 | 124 |
| >=65 years | 60 | 56 | 116 |
| Sex: Female, Male(Participants) | Nanotite Implant | Osseotite Implant | Total |
|---|---|---|---|
| Female | 61 | 64 | 125 |
| Male | 61 | 55 | 116 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2008 to primary completion in Oct 2012, 54 months.
Results were first posted in Feb 2014, 1 year 4 months after primary completion.
Of 39 interventional studies with no phase under Tooth Diseases, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 42. This study's 54 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.